The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

Biogen Inc. has announced a $2 billion investment to expand its manufacturing capabilities at Research Triangle Park (RTP), ...

David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of ...

Amylyx is a high-risk biotech targeting rare diseases with strong cash reserves. Key trials soon may drive a 40% stock upside ...

The Food and Drug Administration on Monday named George Tidmarsh, a longtime biotech executive who has a background in ...

Biogen Inc. is investing $2 billion in its North Carolina RTP site, expanding manufacturing amid tariff talks.

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist ...

The Food and Drug Administration granted Expanded Access Program authorization for NKGen's investigational drug application.

Biogen is investing $2 billion in its U.S. manufacturing footprint — but not in Massachusetts, where the drug company is ...

The biotechnology company Biogen Inc. announced on Monday they are investing an additional $2 billion in central NC’s Research Triangle Park (RTP).

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on ...